Utama › Kegagalan Jantung › California › Mountain View
Kajian klinikal Kegagalan Jantung di Mountain View, CA
15 kajian untuk Kegagalan Jantung sedang mencari peserta di lokasi dalam dan sekitar Mountain View (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
ELEVATE-HFpEF Clinical Study
Mengambil peserta
- Stanford University, Palo Alto · 5 mi jauh
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
Mengambil pesertaFasa 3
- Research Site, Palo Alto · 5 mi jauh
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
Mengambil pesertaFasa 3
- Stanford University Hospital / Stanford Health Care, Stanford · 5 mi jauh
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
Mengambil pesertaFasa 2/3
- Lucile Packard Children's Hospital ( Site 0040), Palo Alto · 5 mi jauh
Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM
Mengambil pesertaKajian pemerhatian
- Research Site, Palo Alto · 5 mi jauh
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Lucile Packard Children's Hospital, Palo Alto · 5 mi jauh
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
Mengambil pesertaKajian pemerhatian
- Stanford, Stanford · 5 mi jauh
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
Mengambil pesertaKajian pemerhatian
- Stanford Health Care Hospital & Clinics, Palo Alto · 5 mi jauh
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
Mengambil pesertaFasa 3
- Tenax Investigational Site, Stanford · 5 mi jauh
CSP #2025 - Geriatric OUt-of-hospital Randomized MEal Trial in Heart Failure: Veterans Affairs (GOURMET-VA)
Mengambil peserta
- VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto · 5 mi jauh
OPtimal Adult Heart Transplant Immunosuppression With MicroRNA Levels
Mengambil pesertaKajian pemerhatian
- Stanford University, Palo Alto · 5 mi jauh
Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System
Mengambil pesertaFasa 2
- Lucile Packard Children's Hospital, Palo Alto · 5 mi jauh
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
Mengambil pesertaFasa 3
- Stanford University Medical Center, Stanford · 5 mi jauh
XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)
Mengambil peserta
- Stanford University, Stanford · 5 mi jauh
Identifying Markers of Exercise Training in Heart Failure
Mengambil peserta
- Stanford Health Care, Stanford · 5 mi jauh
Kajian Kegagalan Jantung di bandar lain
- New York City, NY51 kajian
- Boston, MA44 kajian
- Dallas, TX42 kajian
- Houston, TX36 kajian
- Cleveland, OH33 kajian
- Chicago, IL31 kajian
- Philadelphia, PA31 kajian
- San Francisco, CA29 kajian
- St. Louis, MO26 kajian
- Durham, NC26 kajian
- Kansas City, MO25 kajian
- Atlanta, GA25 kajian
Kajian lain di Mountain View
- Kanser (semua jenis)40 kajian
- Kanser Payudara25 kajian
- Kanser Metastatik25 kajian
- Kanser Paru-paru Bukan Sel Kecil21 kajian
- Leukemia Mieloid Akut19 kajian
- Kanser Ovari19 kajian
- Gangguan Spektrum Autisme17 kajian
- Kanser Paru-paru17 kajian
- Kanser Prostat15 kajian
- Autisme13 kajian
- Leukemia Limfoblastik Akut13 kajian
- Kanser Kolorektal13 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.